Avalanche Biotechnologies, an early stage biotech firm developing gene therapies for wet AMD and other ophthalmic diseases, has set terms for its upcoming IPO. The company plans to offer 5.4 million shares at between $13 and $15 per share. Founded in 2006, the company has raised about $61 million in venture funding to date, most recently landing a $55 million Series B investment at a $168 million valuation this past April. Its major stockholders, none of which will sell shares in the offering, include Venrock (13.2% pre-IPO stake), FMR (8.9%) and Deerfield Management (5.8%), among others. Avalanche aims to trade on the NASDAQ under the symbol AAVL.